Article
The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users.
Breast cancer research and treatment - 1 Nov 2009
Bijl Monique J, van Schaik Ron H N, Lammers Laureen A, Hofman Albert, Vulto Arnold G, van Gelder Teun, Stricker Bruno H Ch, Visser Loes E
Abstract excerpt
Cytochrome P450 2D6 (CYP2D6) plays an important role in the formation of endoxifen, the active metabolite of tamoxifen. In this study the association between the most prevalent CYP2D6 null-allele in Caucasians (CYP2D6*4) and breast cancer mortality was examined among all incident users of tamoxifen in a population-based cohort study. Breast cancer mortality was significantly increased in patients with the * 4/*4...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.